We are live on
!
Find out more
General Atlantic Portfolio holdings
AUM
$2.91B
Turnover
40%
1-Year Est. Return
24.21%
This Fund
S&P 500
This Quarter
Est. Return
+9.73%
1 Year Est. Return
+24.21%
3 Year Est. Return
+168.27%
5 Year Est. Return
+91.75%
10 Year Est. Return
+1,020.11%
AUM
$3.33B
AUM Growth
-$299M
(-8.2%)
Cap. Flow
-$343M
Cap. Flow
% of AUM
-10.3%
Top 10 Holdings %
Top 10 Hldgs %
95.6%
Holding
16
New
1
Increased
3
Reduced
3
Closed
–
Avg Time Held
3.2
years
Top 10 Avg Time Held
2.4
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$96.9M |
| 2 |
Alkami Technology
ALKT
|
+$59.9M |
| 3 |
Pharvaris
PHVS
|
+$11.1M |
| 4 |
Webull Corp
BULL
|
+$725K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alignment Healthcare
ALHC
|
+$292M |
| 2 |
dLocal
DLO
|
+$219M |
| 3 |
Adagene
ADAG
|
+$89.2K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 44.52% |
| 2 | Healthcare | 39.4% |
| 3 | Financials | 14.4% |
| 4 | Consumer Staples | 1.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
dLocal
DLO
$4.32B
| $666M | 20% |
46,656,695
-17,250,000
| -27% | -$219M |
2021 Q2
17 quarters
|
|
2
XP
XP
$14.8B
| $479M | 14.4% |
25,517,733
| – | – |
2019 Q4
23 quarters
|
|
|
3
Alignment Healthcare
ALHC
$1.72B
| $424M | 12.72% |
24,287,227
-19,706,096
| -45% | -$292M |
2021 Q1
18 quarters
|
|
4
Chime Financial
CHYM
$11.2B
| $387M | 11.63% |
19,208,760
| – | – |
2025 Q2
1 quarter
|
|
|
5
Alkami Technology
ALKT
$1.47B
| $298M | 8.94% |
11,991,480
+2,346,162
| +24% | +$59.9M |
2021 Q2
17 quarters
|
|
6
DELISTED
Akero Therapeutics
AKRO
| $272M | 8.17% |
5,733,989
| – | – |
2023 Q2
9 quarters
|
|
|
CNTA
7
DELISTED
Centessa Pharmaceuticals
CNTA
| $235M | 7.05% |
9,681,818
| – | – |
2021 Q2
17 quarters
|
|
|
8
Pharvaris
PHVS
$1.95B
| $200M | 6.02% |
8,031,252
+500,000
| +7% | +$11.1M |
2021 Q1
18 quarters
|
|
|
9
Revolution Medicines
RVMD
$38.1B
| $116M | 3.47% |
+2,474,428
| New | +$96.9M |
2025 Q3
0 quarters
|
|
|
10
Webull Corp
BULL
$3.28B
| $106M | 3.2% |
7,198,867
+50,816
| +0.7% | +$725K |
2025 Q2
1 quarter
|
|
11
Royalty Pharma
RPRX
$27.1B
| $52.9M | 1.59% |
1,500,000
| – | – |
2020 Q2
21 quarters
|
|
12
DELISTED
European Wax Center
EWCZ
| $52.3M | 1.57% |
13,110,492
| – | – |
2021 Q3
16 quarters
|
|
13
Riskified
RSKD
$1.09B
| $24.9M | 0.75% |
5,324,998
| – | – |
2021 Q3
16 quarters
|
|
|
14
Adagene
ADAG
$138M
| $7.53M | 0.23% |
3,782,339
-43,613
| -1% | -$89.2K |
2021 Q1
18 quarters
|
|
15
Alumis Inc
ALMS
$792M
| $5.18M | 0.16% |
1,297,530
| – | – |
2025 Q2
1 quarter
|
|
16
Grove Collaborative
GROV
$41.8M
| $3.71M | 0.11% |
2,474,859
| – | – |
2022 Q2
13 quarters
|
|
Similar funds
General Atlantic's Q3 2025 Portfolio in Review
As of Q3 2025, General Atlantic held 16 positions worth $3.33B, down 8.2% from $3.63B the previous quarter. Its ten largest holdings account for 96% of the portfolio.
General Atlantic withdrew a net $343M in Q3 2025, reducing 3 holdings. Its largest reduction was Alignment Healthcare, cutting an estimated $292M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, down from 49% a quarter earlier, followed by Healthcare and Financials.
Against the trend, General Atlantic opened a new position in Revolution Medicines worth $116M.
- General Atlantic's largest Q3 2025 buy was Revolution Medicines: 2,474,428 shares worth $116M.
- General Atlantic added most to Alkami Technology in Q3 2025, an estimated $59.9M increase.
- General Atlantic's biggest Q3 2025 reduction was Alignment Healthcare, cutting an estimated $292M.
- General Atlantic's ten largest holdings make up 96% of its $3.33B portfolio in Q3 2025.
- General Atlantic opened 1 new position and closed 0 in Q3 2025.
- General Atlantic's portfolio value fell 8.2% quarter-over-quarter to $3.33B.
Based on General Atlantic's 13F filing for Q3 2025, filed 13 Nov 2025.